About
CEVR Team
Careers
Read for the Registry
Contact Us
News & Events
News
Events
Publications
Databases
CEA Registry
GH CEA Registry
SPEC Database
Sponsorship
Sponsor login
Contact Us
News & Events
News
CEVR Announces Two New Members of CEA Registry Scientific Advisory Board
CEVR Announces Two New Members of CEA Registry Scientific Advisory Board CEVR is pleased to welcome two new advisors to the Cost-Effectiveness Analysi...
Call for Papers: 2024 Tufts-CEVR Cost-Effectiveness Analysis Paper of the Year
Call for Papers! 2024 Tufts-CEVR Cost-Effectiveness Analysis Paper of the Year The Center for the Evaluation of Value and Risk in Health (CEVR) at T...
CEVR Participation at ISPOR Europe 2024
CEVR faculty will present their research during several discussion and poster sessions at ISPOR Europe 2024 in Barcelona: Monday, November 19 Breakou...
View All News Items
Events
CEVR Health Policy Seminar | Biosimilar Uptake In The US: Patient And Prescriber Factors
Symposium: Celebrating Cost Effectiveness Analysis
CEVR Health Policy Seminar: Using Real World Data to Assess the Shifting Regulatory Landscape of Pharmaceutical Abortion
View All Events
Publications
Archives of Dermatological Research
Impact on quality of life, health care access, and health care utilization of individuals with vitiligo: an analysis of the All of Us Research Program
JAMA Network Open
Modeling the population equity of Alzheimer Disease treatments in the US
BMJ Global Health
Disparities in availability of new cancer drugs worldwide: 1990-2022
Alzheimer's & Dementia
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
Alzheimer's & Dementia
Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease
Health Affairs Scholar
Public deliberation on health gain measures
Health Affairs
US commercial plans increase choice of biosimilar and originator products; market net prices decrease
Applied Health Economics and Health Policy
Are drug novelty characteristics associated with greater health benefits?
STAT
Medicare’s new transitional coverage of emerging technologies program doesn’t go far enough
View All Publications